Azt-pmap

Cat. No.: HY-120832 Purity: 99.85%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Azt-pmap, a nucleoside analogue, is an aryl phosphate derivative of AZT. Azt-pmap shows anti-HIV activity. AZT is a nucleoside reverse transcriptase inhibitor (NRTI) for HIV infection. Azt-pmap is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

For research use only. We do not sell to patients.

Azt-pmap Chemical Structure

CAS No. : 142629-81-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

Azt-pmap, a nucleoside analogue, is an aryl phosphate derivative of AZT. Azt-pmap shows anti-HIV activity^[1]. AZT is a nucleoside reverse transcriptase inhibitor (NRTI) for HIV infection^[2]. Azt-pmap is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

IC₅₀ & Target^[1]

HIV-1

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	172 μM Compound: 2a	cytotoxic activity in CEM/0 cell line cytotoxic activity in CEM/0 cell line	[PMID: 8478904]
CCRF-CEM	CC₅₀	172 μM Compound: 4 ([PhMeAla]AZT)	Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells. Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	CC₅₀	9.7 x 10^-5 M Compound: 4	Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1 Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1	[PMID: 9871705]
CCRF-CEM	EC₅₀	0.055 μM Compound: 2a	Anti HIV-1 activity in human lymphocyte CEM/0 cell line Anti HIV-1 activity in human lymphocyte CEM/0 cell line	[PMID: 8478904]
CCRF-CEM	EC₅₀	0.055 μM Compound: 4 ([PhMeAla]AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells. Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	0.07 μM Compound: 2a	Anti HIV-2 activity in human lymphocyte CEM/0 cell line Anti HIV-2 activity in human lymphocyte CEM/0 cell line	[PMID: 8478904]
CCRF-CEM	EC₅₀	0.07 μM Compound: 4 ([PhMeAla]AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells. Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	12 μM Compound: 2a	Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase	[PMID: 8478904]
CCRF-CEM	EC₅₀	12 μM Compound: 4 ([PhMeAla]AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells. Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	4.1 x 10^-6 M Compound: 4	Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1 Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1	[PMID: 9871705]
CEM-SS	CC₅₀	> 100 μM Compound: 1	Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line	[PMID: 14521418]
CEM-SS	EC₅₀	0.05 μM Compound: 1	Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line	[PMID: 14521418]
CEM-TK(+)	CC₅₀	> 100 μM Compound: 1	Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line	[PMID: 14521418]
JM1	ED₅₀	0.8 μM Compound: 2d	Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control	10.1016/S0960-894X(00)80395-9
MT4	CC₅₀	> 10 μM Compound: 1	Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line	[PMID: 14521418]
MT4	CC₅₀	> 50 μM Compound: 2a	cytotoxic activity in MT-4 cell line cytotoxic activity in MT-4 cell line	[PMID: 8478904]
MT4	EC₅₀	0.006 μM Compound: 2a	Anti HIV-1 activity in human lymphocyte MT-4 cell line Anti HIV-1 activity in human lymphocyte MT-4 cell line	[PMID: 8478904]
MT4	EC₅₀	0.007 μM Compound: 2a	Anti HIV-2 activity in human lymphocyte MT-4 cell line Anti HIV-2 activity in human lymphocyte MT-4 cell line	[PMID: 8478904]
MT4	EC₅₀	0.34 μM Compound: 1	Effective concentration required to inhibit HIV-1 replication in MT-4 cell line Effective concentration required to inhibit HIV-1 replication in MT-4 cell line	[PMID: 14521418]

In Vitro

Azt-pmap shows anti-HIV-1 activities in infected C8166 and JM cells with EC₅₀s of 0.08 and0.32 μM, respectively. Azt-pmap displays toxicities in infected C8166 and JM cells with TC₅₀s of 500 μM, respectively. Azt-pmap inhibits virus replication^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

508.42

Formula

C₂₀H₂₅N₆O₈P

CAS No.

142629-81-0

Appearance

Solid

Color

White to off-white

SMILES

O=C(NC1=O)N(C=C1C)[C@@H]2O[C@H](COP(OC3=CC=CC=C3)(N[C@@H](C)C(OC)=O)=O)[C@@H](N=[N+]=[N-])C2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (196.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9669 mL	9.8344 mL	19.6688 mL
5 mM	0.3934 mL	1.9669 mL	3.9338 mL
10 mM	0.1967 mL	0.9834 mL	1.9669 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.85%

Select Batch:

Data Sheet (274 KB) SDS (252 KB)

COA (251 KB) HNMR (459 KB) RP-HPLC (235 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. McGuigan C, et al. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. Antiviral Res. 1992 Apr;17(4):311-21. [Content Brief]

[2]. Gray LR, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013 Apr 16;8(4):e62196. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9669 mL	9.8344 mL	19.6688 mL	49.1719 mL
	5 mM	0.3934 mL	1.9669 mL	3.9338 mL	9.8344 mL
	10 mM	0.1967 mL	0.9834 mL	1.9669 mL	4.9172 mL
	15 mM	0.1311 mL	0.6556 mL	1.3113 mL	3.2781 mL
	20 mM	0.0983 mL	0.4917 mL	0.9834 mL	2.4586 mL
	25 mM	0.0787 mL	0.3934 mL	0.7868 mL	1.9669 mL
	30 mM	0.0656 mL	0.3278 mL	0.6556 mL	1.6391 mL
	40 mM	0.0492 mL	0.2459 mL	0.4917 mL	1.2293 mL
	50 mM	0.0393 mL	0.1967 mL	0.3934 mL	0.9834 mL
	60 mM	0.0328 mL	0.1639 mL	0.3278 mL	0.8195 mL
	80 mM	0.0246 mL	0.1229 mL	0.2459 mL	0.6146 mL
	100 mM	0.0197 mL	0.0983 mL	0.1967 mL	0.4917 mL

Azt-pmap Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Azt-pmap142629-81-0HIVHuman immunodeficiency virusderivativeHIV1virusreplicationtoxicitiesinfectionnucleosideanalogueInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *